Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

November 18th 2020

Dr. Subramanian on the Potential Utility of Dostarlimab in Previously Treated NSCLC

November 17th 2020

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in previously treated patients with non–small cell lung cancer.

Dr. Ramalingam on Limitations With Immunotherapy in NSCLC

November 17th 2020

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Tislelizumab Improves Survival in Second- or Third-Line NSCLC

November 17th 2020

November 17, 2020 - The PD-1 inhibitor tislelizumab was found to improve overall survival versus docetaxel in the second- or third-line treatment in patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.

Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era

November 16th 2020

In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.

Next Steps for RET-Mutated Medullary Thyroid Cancer

November 16th 2020

Recent Approval of Selpercatinib in RET-Mutated MTC

November 16th 2020

Multikinase TKIs in Medullary Thyroid Cancer

November 16th 2020

Actionable Driver Mutations in Medullary Thyroid Cancer

November 16th 2020

Epidemiology of Medullary Thyroid Cancer

November 16th 2020

Next Steps for RET Fusion+ NSCLC

November 16th 2020

RET Fusion+ NSCLC and COVID-19

November 16th 2020

Intracranial Response Rates from RET Inhibitors

November 16th 2020

Importance of Frontline RET Inhibition in NSCLC

November 16th 2020

FDA Approval of RET Inhibitors in NSCLC

November 16th 2020

Best Practices for NGS Selection in NSCLC

November 16th 2020

Use of Liquid Biopsy for RET Detection

November 16th 2020

Optimal Detection of RET Fusions

November 16th 2020

Multikinase TKIs for RET Fusion+ NSCLC

November 16th 2020

Biology of RET Genetic Alterations

November 16th 2020